DK1572178T3 - Behandling af mastalgi med 4-hydroxytamoxifen - Google Patents

Behandling af mastalgi med 4-hydroxytamoxifen

Info

Publication number
DK1572178T3
DK1572178T3 DK03813146T DK03813146T DK1572178T3 DK 1572178 T3 DK1572178 T3 DK 1572178T3 DK 03813146 T DK03813146 T DK 03813146T DK 03813146 T DK03813146 T DK 03813146T DK 1572178 T3 DK1572178 T3 DK 1572178T3
Authority
DK
Denmark
Prior art keywords
mastalgia
treatment
hydroxytamoxifen
hydroxy tamoxifen
percutaneously
Prior art date
Application number
DK03813146T
Other languages
Danish (da)
English (en)
Inventor
Lignieres Bruno De
Original Assignee
Besins Int Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Besins Int Lab filed Critical Besins Int Lab
Application granted granted Critical
Publication of DK1572178T3 publication Critical patent/DK1572178T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK03813146T 2002-12-18 2003-12-15 Behandling af mastalgi med 4-hydroxytamoxifen DK1572178T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43395902P 2002-12-18 2002-12-18

Publications (1)

Publication Number Publication Date
DK1572178T3 true DK1572178T3 (da) 2006-09-11

Family

ID=32595255

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03813146T DK1572178T3 (da) 2002-12-18 2003-12-15 Behandling af mastalgi med 4-hydroxytamoxifen

Country Status (15)

Country Link
US (1) US7786172B2 (https=)
EP (1) EP1572178B1 (https=)
JP (1) JP4938237B2 (https=)
AT (1) ATE324880T1 (https=)
AU (1) AU2003303033B2 (https=)
CA (1) CA2509660C (https=)
CY (1) CY1106131T1 (https=)
DE (1) DE60305068T2 (https=)
DK (1) DK1572178T3 (https=)
ES (1) ES2263072T3 (https=)
MX (1) MXPA05006526A (https=)
NZ (1) NZ540494A (https=)
PT (1) PT1572178E (https=)
SI (1) SI1572178T1 (https=)
WO (1) WO2004054557A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4684655B2 (ja) * 2002-12-18 2011-05-18 ラボラトワール ブザン アンテルナスィヨナル 4−ヒドロキシタモキシフェンによる乳房密度低下
CA2519980C (en) * 2003-04-01 2012-04-10 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
US7767717B2 (en) * 2003-06-09 2010-08-03 Ascend Therapeutics, Inc. Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
EP1579856A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579857A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Chemically stable compositions of 4-hydroxy tamoxifen
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
CN1946387B (zh) * 2004-03-22 2011-08-31 法国法杏大药厂 4-羟基三苯氧胺在制备治疗和预防良性乳房疾病的药物中的应用
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
EP1799201B1 (en) * 2004-10-14 2008-11-26 Laboratoires Besins International 4-hydroxy tamoxifen gel formulations
JP5544458B2 (ja) * 2005-07-12 2014-07-09 アンピオ ファーマシューティカルズ,インコーポレイテッド 疾病を治療するための医薬製品の製造においてトリロスタンiiiを使用する方法及びトリロスタンiiiを含む医薬製品
JP5833549B2 (ja) 2009-06-22 2015-12-16 アンピオ ファーマシューティカルズ,インコーポレイテッド 血管透過性亢進を抑制するためのダナゾールを含む製薬組成物
CN104968350A (zh) 2012-12-19 2015-10-07 安皮奥制药股份有限公司 疾病的治疗方法
IL304863B2 (en) 2017-09-11 2025-08-01 Atossa Therapeutics Inc Methods for making and using endoxifen
JP7662204B2 (ja) 2019-07-03 2025-04-15 アトッサ・セラピューティクス・インコーポレイテッド エンドキシフェンの徐放性組成物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
ATE80152T1 (de) 1987-04-21 1992-09-15 Heumann Pharma Gmbh & Co Stabile loesungsmitteladdukte von z-1-(p-betadimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl) 2-phenylbut-1-en.
US5045553A (en) 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
DE3836862A1 (de) 1988-10-27 1990-05-03 Schering Ag Mittel zur transdermalen applikation von steroidhormonen
US5189212A (en) 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
TW218849B (https=) 1991-05-17 1994-01-11 Bristol Myers Squibb Co
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US5720963A (en) 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
IL120268A0 (en) * 1996-02-28 1997-06-10 Pfizer Use of (E)-1-[4'-(2-alkylaminoethioxy)phenyl]1-(3'-hydroxyphenyl)-2-phenylbut-1-enes in inhibiting pathological conditions
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US6548491B2 (en) * 1997-12-24 2003-04-15 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6013270A (en) 1998-04-20 2000-01-11 The Procter & Gamble Company Skin care kit
CA2393762A1 (en) * 1999-12-16 2001-06-21 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
DE10033853A1 (de) 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
EP1177787A3 (en) * 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
DE10054294A1 (de) 2000-11-02 2002-05-16 Heinrich Wieland Topische Behandlung bei der Mastalgie
ATE288303T1 (de) 2000-11-30 2005-02-15 Pfizer Prod Inc Östrogen agonist-antagonist und testosteron enthaltende zusammensetzung zur behandlung abnehmender testosteronspiegel
JP2005504032A (ja) 2001-07-31 2005-02-10 ファイザー・プロダクツ・インク エストロゲン・アゴニスト/アンタゴニスト、エストロゲン及びプロゲスチンの組み合わせを含む医薬組成物、キット及び方法
PT1317921E (pt) 2001-12-07 2009-11-06 Besins Mfg Belgium Composição farmacêutica sob a forma de gel ou de solução à base de di-hidrotestosterona, seu processo de preparação e suas utilizações
JP4684655B2 (ja) 2002-12-18 2011-05-18 ラボラトワール ブザン アンテルナスィヨナル 4−ヒドロキシタモキシフェンによる乳房密度低下
CA2519980C (en) 2003-04-01 2012-04-10 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
US7767717B2 (en) 2003-06-09 2010-08-03 Ascend Therapeutics, Inc. Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579856A1 (en) 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579857A1 (en) 2004-03-22 2005-09-28 Laboratoires Besins International Chemically stable compositions of 4-hydroxy tamoxifen
EP1647271A1 (en) 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations

Also Published As

Publication number Publication date
NZ540494A (en) 2007-05-31
CY1106131T1 (el) 2011-06-08
PT1572178E (pt) 2006-09-29
SI1572178T1 (sl) 2006-10-31
ES2263072T3 (es) 2006-12-01
EP1572178A2 (en) 2005-09-14
HK1075403A1 (en) 2005-12-16
CA2509660C (en) 2011-08-30
DE60305068D1 (de) 2006-06-08
EP1572178B1 (en) 2006-05-03
US7786172B2 (en) 2010-08-31
ATE324880T1 (de) 2006-06-15
AU2003303033A1 (en) 2004-07-09
WO2004054557A2 (en) 2004-07-01
MXPA05006526A (es) 2006-02-17
JP4938237B2 (ja) 2012-05-23
WO2004054557A3 (en) 2004-08-05
AU2003303033B2 (en) 2009-06-04
CA2509660A1 (en) 2004-07-01
JP2006514949A (ja) 2006-05-18
US20050032909A1 (en) 2005-02-10
DE60305068T2 (de) 2007-01-11

Similar Documents

Publication Publication Date Title
DK1572178T3 (da) Behandling af mastalgi med 4-hydroxytamoxifen
CZ2006579A3 (cs) Kožní mikroaktivační systém
WO2004054558A3 (en) Reduction of breast density with 4-hydroxy tamoxifen
IL258702B (en) A pump system for use with organ care systems
EA200802213A1 (ru) Способы лечения заболеваний крови
SE0101387D0 (sv) Novel compounds
EA200601776A1 (ru) Метадоновые композиции местного действия и способы их применения
EA200870019A1 (ru) Лактамовые соединения и способы их применения
DK1797053T3 (da) Phenothiazinium-forbindelse til sårheling
DK1778833T3 (da) Fremgangsmåder til anvendelse af regenerative celler til at fremme sårheling
EA200870091A1 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для снятия боли
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
DK1644076T3 (da) Topisk sammensætning til behandling af akne og rosacea med galvanisk genereret elektricitet
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
SE0401968D0 (sv) Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
BRPI0519218A2 (pt) reduÇço do crescimento de cabelos ou pÊlos
DK1537132T3 (da) Salt af mortin-6-glucuronid
DE602004025683D1 (de) Therapeutische zubereitung für autoimmune erkrankungen
PL369331A1 (pl) Środek antyseptyczny do ran i błon śluzowych
TNSN07139A1 (en) 4-hydroxy tamoxifen gel formulations
DE602005018941D1 (de) Verwendung von winterbohnenkraut (satureja montana) oder seinen extrakten zur herstellung von medikamenten zur behandlung von vorzeitiger ejakulation
ITMI20040145A1 (it) L-moprololo lpiu' tartrato
UA6880U (en) Dental elixir
UA51549A (uk) Спосіб комплексної реабілітації хворих на алкогольну залежність
UA38006A (uk) Хондропротективний препарат